REGENT PACIFIC GROUP LIMITED
勵晶太平洋集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 575)

Voluntary Operational Update

Receipt of Payment from Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd. and Update on Senstend™ Commercialisation in the PRC

This announcement is made by the board (the "**Board**") of directors (the "**Director(s)**") of Regent Pacific Group Limited (the "**Company**", and together with its subsidiaries, the "**Group**") on a voluntary basis.

The Board is delighted to announce that on 31 August 2026 the Group has received a significant net milestone payment of US$4.50 million (or approximately HK$35.10 million), net of the People's Republic of China (the "**PRC**") withholding tax, from 復星萬邦(江蘇)醫藥集團有限公司 (Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd. ("**Fosun**")), pursuant to the licence and collaboration arrangements between the Group and Fosun in respect of Senstend™ in the PRC, further underscoring the continued strength and value of this strategic partnership.

The Board further wishes to update the shareholders of the Company (the "**Shareholders**") and potential investors that the Group looks forward to Fosun commencing commercialisation of Senstend™ in the PRC, which is expected to unlock substantial further value for the Group. Upon such first commercialisation, the Group will be entitled to receive a further payment of US$1.80 million (or approximately HK$14.04 million), net of PRC withholding tax, followed thereafter by ongoing royalties and commercial milestone payments payable to the Group, representing substantial further economic upside under the terms of the arrangements with Fosun, amounting to:

- up to a further US$25 million (or approximately HK$195 million) in aggregate upon achievement of annual net sales thresholds following first commercial sales, representing a meaningful additional revenue opportunity for the Group; and

- attractive tiered percentage royalties on net sales, ranging from the low to mid-teens, offering the Group the potential for a substantial, long-term recurring royalty income stream over the life of the product in the PRC, except that lower payment structures will apply in certain circumstances where a generic product has successfully entered and impacted the market in the PRC.

Senstend™ has the potential to help a significant number of patients in the PRC, estimated at approximately 9 million during its first year of launch and growing to over 170 million by the tenth year, underscoring the substantial scale of this market opportunity for the Group.

The Board is highly encouraged by these developments, which it considers represent a significant and positive step forward in the Group's strategy of monetising its Senstend™ asset in the PRC, one of the world's largest pharmaceutical markets, with substantial further value anticipated for the Group from future royalties and milestone payments as commercialisation progresses. The Company will make further announcements as appropriate in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and as further material developments occur.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

Note: Unless otherwise specified, amounts denominated in US$ have been translated into HK$, for illustrative purposes only, at the exchange rate of US$1.00 = HK$7.80.

By Order of the Board
Regent Pacific Group Limited
Jamie Gibson
Executive Director

Hong Kong, 1 September 2026

As at the date of this announcement, the Board comprises six Directors:

Executive Director:
Jamie Gibson *(Chief Executive Officer)*

Non-Executive Directors:
James Mellon *(Chairman)*
Jayne Sutcliffe

Independent Non-Executive Directors:
Mark Searle
Adrian Chan
Ihsan Al Chalabi